Author

Toshifumi Hibi 1

1 Kitasato Institute Hospital Center for Advanced IBD Research and Treatment,Tokyo,Japan

A PHASE 3 STUDY OF VEDOLIZUMAB IN JAPANESE PATIENTS WITH ULCERATIVE COLITIS: EFFECTS ON TIME TO DISEASE WORSENING AND TREATMENT FAILURE

Satoshi Motoya, Kenji Watanabe, Haruhiko Ogata, Takanori Kanai, Toshiyuki Matsui, Yasuo Suzuki, Mitsuhiro Shikamura, Kenkichi Sugiura, Kazunori Oda, Tetsuharu Hori, Takahiro Araki, Mamoru Watanabe, Toshifumi Hibi

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

Marla C. Dubinsky, Remo Panaccione, James D Lewis, Bruce E. Sands, Toshifumi Hibi, Scott D. Lee, April Naegeli, Mingyang Shan, Linden Green, Nathan Morris, Vipin Arora, Alison Potts Bleakman, Ruth Belin, Simon Travis

ADALIMUMAB ACHIEVES COMPLETE REMISSION AT 52 WEEKS IN JAPANESE PATIENTS WITH INTESTINAL BEHÇET'S DISEASE

Fumihito Hirai, Satoshi Tanida, Nagamu Inoue, Makoto Naganuma, Anne Camez, Bidan Huang, Vipin Arora, Morio Ozawa, Toshifumi Hibi, Roopal B Thakkar

ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION

David Clemow, Christophe Sapin, Toshifumi Hibi, Marla C. Dubinsky, Severine Vermeire, Stefan Schreiber, Theresa Hunter Gibble, Laurent Peyrin-Biroulet, Mamoru Watanabe, Remo Panaccione

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

Severine Vermeire, Alessandra Oortwijn, Simon Hatch, Silvio Danese, Toshifumi Hibi, Brian Feagan, William J. Sandborn

BOWEL URGENCY COMMUNICATION GAP BETWEEN HEALTH CARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

Simon Travis, Alison Potts Bleakman, David T. Rubin, Marla C. Dubinsky, Remo Panaccione, Toshifumi Hibi, Theresa Hunter Gibble, Cem Kayhan, Eoin J. Flynn, Christophe Sapin, Christian Atkinson, Stefan Schreiber

CORTICOSTEROID-FREE REMISSION OF ULCERATIVE COLITIS WITH FILGOTINIB MAINTENANCE THERAPY: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Edward V Loftus Jr, Severine Vermeire, Brian Feagan, Chohee Yun, Jeremy Hsieh, Xiaopeng Liu, Sally Zhao, Ulrik Moerch, William J. Sandborn, Toshifumi Hibi

EARLY REDUCTION OF BOWEL WALL THICKNESS BY TRANSPERINEAL ULTRASONOGRAPHY PREDICTS BIOLOGICS-INDUCED DEEP REMISSION IN ULCERATIVE COLITIS

Shintaro Sagami, Taku Kobayashi, Ryo Karashima, Aya Hojo, Hiromu Morikubo, Yusuke Miyatani, Tomohiro Fukuda, Kunio Asonoma, Masaru Nakano, Toshifumi Hibi

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Laurent Peyrin-Biroulet, Bruce E. Sands, William Sandborn, Peter D.R. Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, Vipin Arora, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES

Simon Travis, Toshifumi Hibi, Tadakazu Hisamatsu, Deborah Fisher, Mingyang Shan, Theresa Hunter Gibble, David T. Rubin

Item 1 - 10 / 50
1
2 3 4 5